SNNA Sienna Biopharmaceuticals Inc.

1.06
0  0%
Previous Close 1.06
Open 1.07
Price To Book 0.97
Market Cap 32,374,497
Shares 30,541,978
Volume 125,101
Short Ratio
Av. Daily Volume 163,660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met non-inferiority primary endpoint - February 8, 2019. Seeking partner for further advancement.
SNA-001
Reduction of light-pigmented hair
Phase 3 data released July 30, 2018 did not meet primary endpoint.
SNA-001
Acne
Phase 2b trial did not meet primary endpoint. Phase 3 trial to be initiated 2H 2019.
SNA-120
Pruritus associated with psoriasis
Phase 1/2 data released August 27, 2018.
SNA-125
Psoriasis
Phase 2 trial planned.
SNA-125
Atopic dermatitis

Latest News

  1. Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
  2. Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
  3. Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
  4. Sienna Biopharmaceuticals to Present at BAML Health Care Conference
  5. Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
  6. Introducing Sienna Biopharmaceuticals (NASDAQ:SNNA), The Stock That Tanked 90%
  7. Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
  8. Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  9. Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
  10. Why A Secondary Offering Is Often Negative For Stocks
  11. Sienna Biopharmaceuticals Prices Public Offering of Common Stock
  12. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  13. Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock
  14. 4 Tech Stocks Leading The Pack On Friday (2/8/19)
  15. Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System
  16. Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
  17. Do Directors Own Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) Shares?
  18. Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK)
  19. Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
  20. Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019